ClinicalTrials.gg
SuspendedNCT07433062IRAK4Updated Apr 22, 2026

A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus

A Phase 1 interventional study of AZD6793 and AZD6793 Placebo in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Suspended at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

Why this study was suspended
Safety issue was identified in the Phase2b D7860C00006 study, evaluating AZD6793 in moderate to very severe COPD participants. D7860C00005 study is temporary halted to amend the design to reflect changes implemented in the ongoing D7860C00006 study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca — 13 open to participants now, 15 under way, 9 of them phase 3. Diabetes Mellitus, Type 2 · AstraZeneca.

Planned enrollment
228th of 280
28 · median 155
Started
2026
with 13 others
Phase 1
86 of 345
2 open now
Registered
331st of 345
by date

Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 228th largest by planned enrollment of the 280 interventional ones that give a count, is one of 14 that started in 2026, is one of 86 in phase 1, and was the 331st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

13 of the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to examine the effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus.

Read the detailed description

This is a double-blind, placebo-controlled, 2-period cross-over study conducted at a single study centre to assess the pharmacokinetics and pharmacodynamics (ie, glucose lowering effect) of metformin in participants with T2DM when metformin is administered alone and in combination with multiple doses of AZD6793. This study will consist of 2 treatment periods separated by a washout period of 7 to 14 days.

Approximately 28 eligible participants will be randomized to study intervention such that 24 evaluable participants complete the study (12 participants in each treatment sequence).

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Diabetes
  • T2DM
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physician-diagnosis of T2DM
  • On a stable dose of metformin 2000 mg per day for at least 3 months prior to screening.
  • stable glycaemic control indicated by no change in treatment for diabetes within 3 months prior to screening
  • (Hemoglobin A1c) ≤ 8.5% at screening
  • (BMI) within the range 18.5 to 35 kg/m2 , inclusive, at screening.

Exclusion criteria

Exclusion Criteria:

  • Physician diagnosis of type 1 diabetes.
  • History of any disease or disorder.
  • History or presence of chronic Gastrointestinal, hepatic, renal, or pancreatic disease
  • History of Human immunodeficiency viruses () infection or a positive HIV test.
  • History of prior episode(s) of lactic acidosis.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Treatment A

    AZD6793 and metformin

    Drug: AZD6793

  • Experimental
    Treatment B

    Placebo and metformin

    Drug: AZD6793 Placebo

Interventions

  • Participants will receive oral doses of metformin with an interval of 12 hours between doses. The morning doses of metformin will be administered together with AZD6793 (Treatment A).

    Also known as: Active

  • DrugAZD6793 Placebo

    Participants will receive oral doses of metformin with an interval of 12 hours between doses. The morning doses of metformin will be administered together with AZD6793 placebo (Treatment B).

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Mean glucose levels

    Mean glucose levels on Day 7 of each treatment period as assessed by Continuous Glucose Monitoring (CGM)

    Time frame: Day 7

Secondary outcomes

  1. CGM Metric (Time in range)

    The percentage of time (or hours/day) that blood glucose levels remain within a target

    Time frame: Day 7 of each treatment period

  2. CGM Metric (Time in tight range)

    A metric measuring the percentage of time blood glucose remains between a pre-defined range.

    Time frame: Day 7 of each treatment period

  3. CGM Metric (time below range)

    A metric representing the percentage of time and minutes per day spent with blood glucose below a certain range.

    Time frame: Day 7 of each treatment period

  4. CGM Metric (time above range)

    A metric representing the percentage of time and minutes per day spent with blood glucose above a certain range.

    Time frame: Day 7 of each treatment period

  5. CGM Metric (AUC(0-24))

    area under the concentration-time curve from time 0 to 24 hours postdose

    Time frame: Day 7 of each treatment period

  6. CGM Measure (Plasma fasting glucose)

    A measure of glucose levels when a participant is in a fasting state.

    Time frame: Day 7 of each treatment period

  7. CGM Measure (AUC(0-4) after each meal)

    area under the concentration-time curve from time 0 to 4 hours postdose after each meal

    Time frame: Day 7 of each treatment period

  8. CGM Measure (Total glucose AUC(0-24))

    area under the concentration-time curve from time 0 to 24 hours postdose

    Time frame: Day 7 of each treatment period

  9. Metformin Plasma PK (AUC(0-12))

    area under the concentration-time curve from time 0 to 12 hours postdose

    Time frame: Day 7 of each treatment period

  10. Metformin Plasma PK (Cmax)

    maximum observed concentration

    Time frame: Day 7 of each treatment period

  11. Metformin Plasma PK (tmax)

    time to reach maximum observed plasma concentration

    Time frame: Day 7 of each treatment period

  12. Metformin Plasma PK (t1/2λz)

    Terminal elimination half-life

    Time frame: Day 7 of each treatment period

  13. Metformin Plasma PK (CL/F)

    apparent total body clearance

    Time frame: Day 7 of each treatment period

  14. Metformin Plasma PK (Vz/F)

    apparent volume of distribution during the terminal phase.

    Time frame: Day 7 of each treatment period

  15. Metformin Plasma PK (R AUC(0-12))

    Ratio of test to reference based on AUC(0-12)

    Time frame: Day 7 of each treatment period

  16. Metformin Plasma PK (R Cmax)

    Ratio of test to reference based on Cmax

    Time frame: Day 7 of each treatment period

  17. Metformin Urine PK (Ae(0-12))

    cumulative amount excreted into the urine from time 0 to 12 hours postdose

    Time frame: Day 7 of each treatment period

  18. Metformin Urine PK (fe(0-12))

    Percentage of dose excreted unchanged in urine from time zero to 12 hours post-dose

    Time frame: Day 7 of each treatment period

  19. Metformin Urine PK (CLR)

    renal clearance from plasma

    Time frame: Day 7 of each treatment period

  20. AZD6793 plasma PK (AUC(0-24))

    area under the concentration-time curve from time 0 to 24 hours postdose

    Time frame: Days 1 through 7 of each treatment period

  21. AZD6793 plasma PK (Cmax)

    maximum observed concentration

    Time frame: Days 1 through 7 of each treatment period

  22. AZD6793 plasma PK (tmax)

    time to reach maximum observed plasma concentration

    Time frame: Days 1 through 7 of each treatment period

  23. AZD6793 plasma PK (t1/2λz)

    Terminal elimination half-life

    Time frame: Days 1 through 7 of each treatment period

  24. AZD6793 plasma PK (Ctrough)

    concentration observed immediately prior to dosing

    Time frame: Days 1 through 7 of each treatment period

  25. AZD6793 plasma PK (Rac AUC(0-24))

    accumulation ratio based on AUC(0-24)

    Time frame: Days 1 through 7 of each treatment period

  26. AZD6793 plasma PK (Rac Cmax)

    Accumulation ration based on Cmax

    Time frame: Days 1 through 7 of each treatment period

07

Study locations

1 site
  • Research Site
    Neuss, 41460, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Jun 2026, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2025
First posted
Feb 25, 2026
StartActual
Jan 14, 2026
Primary completionEst.
Jun 18, 2026
CompletionEst.
Jun 18, 2026
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07433062
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Jan 14, 2026
Primary completion
Jun 18, 2026 (estimated)
Completion
Jun 18, 2026 (estimated)
Last update
Apr 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD6793

Start the discussion